

7M2026 BUSINESS UPDATES



Imexpharm Corporation



July Performance

OTC channel shows positive signs of recovery

Gross revenue and gross profit declined by 8% and 3% y-o-y, respectively.

PBT grew 7% y-o-y, supported by effective COGS control, with COGS down 20% y-o-y.

Revenue from pharmacy chains increased significantly, driving 12% y-o-y growth in the OTC channel.



7-Month Performance

Sustained profit growth driven by operational efficiency

Gross revenue and net revenue reached VND 1,491 billion and VND 1,264 billion, respectively, down 10% y-o-y.

7M PBT and EBITDA grew 5% and 1% y-o-y, respectively, underpinned by continued improvements in factory utilization, optimized manufacturing costs, and tightened selling and administrative expense.

BUSINESS HIGHLIGHTS

01

TRANSPARENT GOVERNANCE

Information Disclosure Best Practices 2026

(Vietstock, VAFE Association, and Fili Electronic Magazine)



02

PARTNERSHIP WITH PHARMACY

Enhancing consulting capabilities for pharmacy pharmacists

